Navigation Links
Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
Date:7/23/2008

ROCKVILLE, Md., July 23 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended June 30, 2008. These results are expected to be disclosed on Wednesday, July 30, 2008, after the capital markets close.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

The conference call will be hosted by senior management and will be held on Wednesday, July 30, 2008 at 5:00 pm Eastern Time.

Investors may listen to the call by dialing (913) 312-0412 or (888) 686-9685 passcode 4551709, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing (719) 457-0820 or 888-203-1112 confirmation code 4551709.

This conference call also will be webcast and may be accessed at http://www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New map IDs the core of the human brain
2. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
3. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
4. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
5. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
6. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
7. Robots moving closer to humans
8. Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes
9. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
10. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
11. Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... mass flow controllers based on capillary thermal mass flow technology provide exponentially more ... control applications. Over 80% of all industrial processes—such as those involving chemical ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... joined other scientists, researchers, engineers, and industry professionals in visiting U.S. Congressional offices ... to compete in the world photonics industry. , This year, National Photonics ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... Lajollacooks4u, San Diego’s premiere team-building and cooking events company, offers one-of-a-kind gifts, ranging ... , Menus specialize in California cuisine, and guests leave inspired with new cooking ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):